O-RAY PHARMA, INC.

Basic Information

2285 EAST FOOTHILL BLVD
PASADENA, CA, 91107-3658

Company Profile

n/a

Additional Details

Field Value
DUNS: 800316361
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Prevention of Children's Tympanostomy Tube Otorrhea

    Amount: $159,277.00

    DESCRIPTION (provided by applicant): Otitis media (infection of the middle ear space) is one of the most common diseases of childhood. Myringotomy with tympanostomy tube (TT) insertion is the most com ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Sustained Release Inner Ear Delivery of Corticosteroid

    Amount: $1,337,994.00

    DESCRIPTION (provided by applicant): Cochlear implants have restored hearing in thousands of patients over the last two decades. However, because residual hearing is damaged in the process of insertio ...

    SBIR Phase II 2014 Department of Health and Human Services
  3. Ototoxicity protection with intratympanic steroid implant

    Amount: $154,472.00

    DESCRIPTION (provided by applicant): Chemotherapy-induced ototoxicity is damage to the inner ear that is caused by the side effects of administered drugs. This can lead to permanent hearing loss and/o ...

    SBIR Phase I 2012 Department of Health and Human Services
  4. Sustained Release Inner Ear Delivery of Corticosteroid

    Amount: $1,071,370.00

    DESCRIPTION (provided by applicant): Project Summary The broad long term goal of this research program is to reduce or eliminate deafness by developing sustained release intracochlear drug deliver ...

    SBIR Phase II 2010 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government